Mineralys Therapeutics, Inc.
NASDAQMineralys Therapeutics entered its Q1 results week with short sellers quietly adding pressure and options traders having already rotated to a more bullish stance — a setup that frames the next catalyst squarely around the FDA. The week's headline event landed after the close on May 6. Q1 EPS came in at -$0.47, in line with consensus. One headline noted the company beat by $0.34 — a…
Snapshot as of 7 May 2026
Mineralys Therapeutics entered its Q1 results week with short sellers quietly adding pressure and options traders having already rotated to a more bullish stance — a setup that frames the next catalyst squarely around…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MLYS — free to start on ORTEX.
Sign up for free →Open MLYS on ORTEX